Galantamine

Basic galantamine information

• INN (international nonproprietary name): Galantamine
• Brand names available in the United Kingdom: Reminyl, Reminyl XL; generic galantamine
• ATC code: N06DA04
• Forms & Dosages: Immediate‑release tablets 4mg, 8mg, 12mg; extended/prolonged‑release capsules 8mg, 16mg, 24mg; oral solution 4mg/mL
• Manufacturers in the United Kingdom: Janssen‑Cilag (originator Reminyl); generics include Gedeon Richter, Zentiva, Sandoz, Teva, Accord Healthcare, Mylan
• Registration status in the United Kingdom: Licensed; prescription only
• OTC / Rx classification: Prescription only (Rx)

Legal status and availability in the UK

Galantamine (Reminyl and generics) is a prescription-only medicine (POM) in the UK.

In our online pharmacy, galantamine is available with discreet delivery to the United Kingdom in 9–21 days.

Clinical effectiveness in the UK

Will galantamine make a noticeable difference for my relative?

In NHS practice, galantamine (Reminyl and generics) is prescribed for symptomatic treatment of mild to moderate Alzheimer’s disease in line with NICE and MHRA principles for acetylcholinesterase inhibitors.

In practice, some patients show stabilisation or small improvements in cognition and daily activities over months, while others have minimal benefit.

Responders often show improvement within three to six months, prompting clinicians to reassess at those intervals and consider stopping if no meaningful clinical gain is apparent.

Some people show increased day‑to‑day engagement, but persistent gastrointestinal side effects remain a frequent reason for early discontinuation.

Standard dosing starts at 4mg twice daily for immediate‑release or 8mg once daily for prolonged‑release, titrated to a target of 16–24mg/day depending on tolerance.

• Monitoring checklist: baseline pulse and ECG where indicated; weight; review for nausea/vomiting/diarrhoea; reassess cognition and function at 3–6 months.

MHRA guidance recommends vigilance for bradycardia and signs of cholinergic excess, and reporting serious events to the Yellow Card scheme.

Indications and expanded uses

Is galantamine licensed for anything beyond Alzheimer’s?

In the UK, galantamine is licensed for the symptomatic treatment of mild to moderate Alzheimer’s disease and is prescription only.

In UK practice this aligns with NHS prescribing guidance where galantamine is offered alongside donepezil and rivastigmine as a cholinesterase inhibitor option.

Off‑label use is uncommon and generally discouraged outside research or specialist settings, as robust licence support is lacking for other cognitive syndromes.

1. Approved indication: Symptomatic treatment of mild to moderate Alzheimer’s disease (ATC N06DA04).
2. Off‑label uses: Rare, mainly confined to clinical trials or specialist assessments; obtain informed consent and document rationale if considered.

Contraindications and cautions apply when considering any expanded use, including severe renal or hepatic impairment, active peptic ulcer disease and significant cardiac conduction disorders.

When off‑label prescribing is contemplated, clinicians should document the decision, record baseline cardiovascular and gastrointestinal risk assessments and obtain informed consent from the patient or their legal representative.

Composition and brand landscape

Which brands and formulations are commonly stocked in UK pharmacies?

The active ingredient is galantamine, usually formulated as galantamine hydrobromide in many marketed products.

The originator brand Reminyl (Janssen‑Cilag) is well known in the UK, with multiple generics available from manufacturers such as Gedeon Richter, Zentiva, Sandoz, Teva, Accord Healthcare and Mylan.

Immediate‑release tablets are available at 4mg, 8mg and 12mg strengths and prolonged‑release capsules are supplied in 8mg, 16mg and 24mg strengths.

Contraindications and special precautions

What conditions mean galantamine should not be used?

Absolute contraindications include hypersensitivity to galantamine or its excipients, severe hepatic or severe renal impairment, recent or active gastric or duodenal ulcers, and severe bradycardia or uncompensated conduction disorders.

Relative cautions include asthma or chronic obstructive pulmonary disease due to bronchospasm risk, seizure disorders, urinary outflow obstruction and sick sinus syndrome.

Clinicians should perform baseline cardiovascular checks and consider an ECG in elderly patients or those with cardiac history.

• Lifestyle advice: driving may be affected if dizziness or syncope occurs; alcohol can worsen sedation and GI effects and should be minimised.
• Pregnancy and lactation: insufficient data — avoid unless expected benefit outweighs risk.

Record precautions in the patient record and advise carers to report fainting, palpitations or severe gastrointestinal symptoms promptly.

Serious cardiovascular events should be reported to the MHRA Yellow Card scheme to help monitor safety in UK practice.

Dosage guidelines (NHS-aligned)

How should galantamine be started and titrated for older patients?

Standard NHS dosing for Alzheimer’s disease is to start immediate‑release at 4mg twice daily or to start prolonged‑release at 8mg once daily.

Titrate every four weeks as tolerated to a maintenance target of 16–24mg/day, with divided doses for immediate‑release formulations.

For moderate hepatic or renal impairment limit the dose to a maximum of 16mg/day and titrate more slowly; severe impairment is not recommended.

1. Start: IR 4mg twice daily or PR 8mg once daily.
2. Titrate: increase every 4 weeks to reach 16–24mg/day as tolerated.
3. Adjustments: moderate hepatic/renal impairment — max 16mg/day; severe impairment — contraindicated.

Missed doses should be taken when remembered unless the next dose is imminent; do not double doses.

In overdose, a cholinergic crisis may occur with nausea, vomiting and bradycardia — urgent medical care is required and management is supportive.

Interactions overview

Can galantamine be given safely with my other medicines?

Galantamine is metabolised via CYP2D6 and CYP3A4, so inhibitors such as fluoxetine, paroxetine and ketoconazole may raise plasma levels, while inducers such as carbamazepine and rifampicin may lower effect.

Pharmacodynamic interactions include additive cholinergic or bradycardic effects with beta‑blockers, other acetylcholinesterase inhibitors, certain antipsychotics and some antiarrhythmics.

Concomitant anticholinergic drugs will reduce galantamine’s clinical effect and should prompt a medication review.

Alcohol amplifies central nervous system and gastrointestinal adverse effects and should be minimised during treatment.

Encourage reporting of unexpected serious adverse events to the MHRA Yellow Card scheme and liaise with prescribers about dose adjustments where interactions are likely.

Comparable medicines and prescribing preferences

Should the prescriber choose galantamine over donepezil or rivastigmine?

NHS prescribers commonly choose between donepezil, rivastigmine and galantamine for mild–moderate Alzheimer’s and memantine for moderate to severe disease.

Donepezil is familiar to many clinicians and is once daily, rivastigmine is available as a transdermal patch which can reduce gastrointestinal adverse effects for some patients, and galantamine offers acetylcholinesterase inhibition plus nicotinic allosteric modulation which may give incremental benefit in selected patients.

Side‑effect profiles differ: galantamine and rivastigmine often cause more gastrointestinal symptoms, whereas donepezil may be better tolerated in some older patients.

• Points to consider: cardiac conduction issues (avoid or monitor galantamine with bradycardia), GI ulcer history (avoid if active), patient preference for patch vs oral, and polypharmacy.

Choice should be individualised, balancing comorbidity, route of administration and likely adherence.

Frequently asked questions

• Will galantamine cure my dementia?

  No. Galantamine is a symptomatic treatment that may stabilise or modestly improve cognition or function for some patients, usually assessed over several months.

• What are the common side effects and what should I do?

  Common side effects include nausea, vomiting, diarrhoea and dizziness; contact your GP or pharmacist if these are persistent or severe and seek urgent care for fainting or severe palpitations.

• Can I drink alcohol or take my other medicines?

  Alcohol should be minimised as it can worsen central and gastrointestinal effects; always tell your GP or pharmacist about all medicines because galantamine is metabolised by CYP2D6 and CYP3A4 and can interact with drugs that cause bradycardia.

• How long will I be kept on it?

  Treatment is reviewed at three to six months and periodically thereafter; the drug is discontinued if no meaningful clinical benefit is observed.

Patients and carers are encouraged to report adverse reactions to the MHRA Yellow Card scheme when appropriate.

Guidelines for proper use (pharmacist counselling and NHS portals)

What should a pharmacist cover when dispensing galantamine?

Confirm the diagnosis and current prescriber, clarify whether the patient has IR or PR formulation and the titration schedule, and review the full medication list for CYP or cardiac interactions.

Explain common side‑effect management — for example, take tablets with food to reduce nausea and report persistent gastrointestinal upset.

Advise on missed dose guidance and actions for overdose, and arrange baseline pulse and ECG where indicated, especially for elderly patients or those on beta‑blockers.

• Documentation items: record counselling in pharmacy notes, communicate concerns to the GP or memory clinic and encourage Yellow Card reporting for serious events.

Encourage registration on NHS patient portals for prescription tracking and direct patients to Alzheimer’s Society resources for carer support.

Storage advice: store tablets at 20–25°C, protect from moisture and light and keep out of reach of children.

Delivery across the United Kingdom